LivaNova PLC (NASDAQ:LIVN) insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $84.48, for a total transaction of $126,720.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
LivaNova traded up $0.63, reaching $83.86, on Friday, MarketBeat reports. The stock had a trading volume of 263,600 shares, compared to its average volume of 485,506. The firm has a market cap of $4.03 billion, a PE ratio of 25.34, a price-to-earnings-growth ratio of 2.62 and a beta of 0.77. LivaNova PLC has a 1-year low of $54.67 and a 1-year high of $92.31. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.03.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 2nd. The company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.03. The firm had revenue of $250.40 million for the quarter, compared to analyst estimates of $245.18 million. LivaNova had a negative net margin of 1.99% and a positive return on equity of 8.38%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 earnings per share. research analysts expect that LivaNova PLC will post 3.18 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its stake in shares of LivaNova by 1,050.6% in the first quarter. Royal Bank of Canada now owns 7,168 shares of the company’s stock worth $634,000 after acquiring an additional 6,545 shares during the last quarter. Legal & General Group Plc raised its stake in shares of LivaNova by 13.6% in the first quarter. Legal & General Group Plc now owns 46,111 shares of the company’s stock worth $4,081,000 after acquiring an additional 5,537 shares during the last quarter. Highbridge Capital Management LLC bought a new position in shares of LivaNova in the first quarter worth about $720,000. Millennium Management LLC raised its stake in shares of LivaNova by 23.0% in the first quarter. Millennium Management LLC now owns 717,478 shares of the company’s stock worth $63,497,000 after acquiring an additional 134,035 shares during the last quarter. Finally, Point72 Europe London LLP bought a new position in shares of LivaNova in the first quarter worth about $3,130,000. Hedge funds and other institutional investors own 86.12% of the company’s stock.
Several brokerages have recently weighed in on LIVN. ValuEngine lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research lowered shares of LivaNova from a “hold” rating to a “strong sell” rating in a research report on Thursday. BTIG Research restated a “hold” rating on shares of LivaNova in a research report on Thursday, May 3rd. BidaskClub lowered shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Saturday, March 10th. Finally, Canaccord Genuity boosted their price target on shares of LivaNova from $76.00 to $81.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $81.43.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.